Jordyn Fantuzzi's questions to Marker Therapeutics (MRKR) leadership • Q1 2020
Question
Jordyn Fantuzzi, on for Ed at Piper Sandler, asked about the commitment shares under the Aspire Capital purchase agreement, questioning the price per share and if the potential capital was included in the company's reported cash position for the quarter.
Answer
CFO Tony Kim explained that the company has not yet drawn down any capital from the Aspire agreement and that the current cash balance of $40.3 million does not necessitate an immediate draw. President and CEO Peter Hoang added that the potential funds from the Aspire facility are not reflected in the company's cash runway guidance, which is based on cash on hand.